8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

Current Report Pursuant

to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) September 14, 2006

PRESSURE BIOSCIENCES, INC.

(Exact Name of Registrant as Specified in its Charter)

MASSACHUSETTS

(State or Other Jurisdiction of Incorporation)

0-21615	04-2652826
(Commission File Number)	(I.R.S. Employer Identification No.)
321 Manley Street, West Bridgewater, MA	02379
(Address of Principal Executive Offices)	(Zip Code)

(508) 580-1818

(Registrant’s Telephone Number, Including Area Code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 4.01Changes in Registrants Certifying Accountant.

(a) Previous Independent Registered Public Accounting Firm

On September 14, 2006, the Audit Committee of the Board of Directors of Pressure BioSciences, Inc. (the “Company”) terminated the appointment of Weinberg & Co. (“Weinberg”) as the Company’s independent registered public accounting firm.  

Weinberg's reports on the Company’s consolidated financial statements for the fiscal years ended December 31, 2005 and 2004 did not contain any adverse opinion or a disclaimer of opinion, nor were the reports qualified or modified as to uncertainty, audit scope or accounting principle.

During the Company’s fiscal years ended December 31, 2005 and 2004 and through the date hereof, there were no disagreements with Weinberg on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of Weinberg, would have caused it to make reference thereto in its reports on the Company’s financial statements for such years.

During the Company’s fiscal years ended  December 31, 2005 and 2004 and through the date hereof, there were no reportable events as described in Item 304(a)(1)(v) of Regulation S-K.

The Company requested that Weinberg furnish it with a letter addressed to the Securities and Exchange Commission stating whether or not it agrees with the above statements. A copy of such letter, dated September 15, 2006, is filed as Exhibit 16.1 to this Form 8-K.

(b) Engagement of New Independent Registered Public Accounting Firm.

On September 14, 2006, the Audit Committee of the Board of Directors of the Company engaged UHY LLP (“UHY”) to serve as the Company’s independent registered public accounting firm.

During the fiscal years ended  December 31, 2005 and 2004 and through the date hereof, neither the Company nor anyone on its behalf consulted with UHY  with respect to any matters or events, including any matters or events set forth and described in Items 304(a)(2)(i) and (ii) of Regulation S-K.

2

Item 9.01 Financial Statements and Exhibits

(d)Exhibits

Exhibit Number	Exhibit Description
16.1	Letter from Weinberg & Co. to the Securities and Exchange Commission dated September 15, 2006
99.1	Press Release dated September 20, 2006

3

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: September 20, 2006	PRESSURE BIOSCIENCES, INC.
	By:	/s/ Richard T. Schumacher
		Richard T. Schumacher, President and Chief
		Executive Officer

4

EXHIBIT INDEX

Exhibit Number	Exhibit Description
16.1	Letter from Weinberg & Co. to the Securities and Exchange Commission dated September 15, 2006
99.1	Press Release dated September 20, 2006

5

EX-16.1

EX-99.1

Investor Contacts:
Richard T. Schumacher, President & CEO	Pressure BioSciences, Inc.
Edward H. Myles, Vice President of Finance & CFO	(508) 580-1818 (T)

Pressure BioSciences, Inc. Selects UHY, LLP

as the Company’s Independent Registered Public Accounting Firm

West Bridgewater, MA, September 20, 2006 - Pressure BioSciences, Inc. (NASDAQ: PBIO) today announced that it has selected UHY, LLP to be the Company's independent registered public accounting firm, effective immediately. UHY, LLP replaces Weinberg & Co., who served as the Company’s independent registered public accounting firm since 2003. The selection of a new auditing firm was not the result of any disagreement between the Company and its previous auditors on any matter of accounting practices or financial disclosure.

UHY, LLP was ranked the 15th largest professional services firm in the US, according to the 2006 Top 100 Accounting Firms in Accounting Today, and serves public companies and middle market and privately-owned companies in multiple industry segments.

Pressure BioSciences, Inc. selected UHY, LLP principally based on its depth of knowledge; experience in the middle market; and its local, national, and international presence. The firm has 16 offices in the United States and is an independent member of UHY International, which has over 150 offices in 50 countries.

With more than thirty years of experience, UHY, LLP is registered with the Public Company Accounting Oversight Board ("PCAOB") to perform audits of financial statements and internal controls of SEC registrants, and PBI is pleased to have engaged an audit firm that has such depth and experience to serve the Company's audit and compliance needs for the foreseeable future.

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (PBI) is a publicly traded, early-stage company focused on the development of a novel, enabling technology called Pressure Cycling Technology (PCT). PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels (up to 35,000 psi and greater) to control bio-molecular interactions. PBI currently holds 13 US and 5 foreign patents covering multiple applications of PCT in the life sciences field, including such areas as genomic and proteomic sample preparation, pathogen inactivation, the control of enzymes, immunodiagnostics, and protein purification.

Forward Looking Statements

Statements contained in this press release regarding the Company’s intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking'' statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based upon the Company’s current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading "Risk Factors" in the Company’s Quarterly Report on Form 10-QSB for the quarter ended June 30, 2006, in the Company’s Annual Report on Form 10-KSB, as amended, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

Visit us at our website http://www.pressurebiosciences.com